Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The researchers aimed to examine cell specific MP profiles and concentrations of MPs expressing the atherosclerotic markers ICAM-1 and VCAM-1 after treatment with paricalcitol in patients with CKD stage 3-4.

Why It Was Studied

Microparticles (MPs) are biomarkers and mediators of disease through their expression of surface receptors, reflecting activation or stress in their parent cells.

Chronic kidney disease (CKD) patients have endothelial dysfunction and high levels of endothelial derived MPs.

Who Took Part

The abstract describes 36 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

MPs were measured by flow cytometry after labelling with antibodies against endothelial (CD62E), platelet (CD62P, CD41, CD154) leukocyte (CD45) and vascular (CD54, CD106) markers.

What Was Measured

Chronic kidney disease (CKD) patients have endothelial dysfunction and high levels of endothelial derived MPs.

PubMed files the paper under topics including Cell-Derived Microparticles, Ergocalciferols, Intercellular Adhesion Molecule-1, Receptors, Calcitriol, Renal Insufficiency, Chronic and Vascular Cell Adhesion Molecule-1.

The authors tagged it with the keywords Chronic kidney disease, Endothelial function, ICAM-1 and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 36 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (BMC nephrology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.